Home - Products - Angiogenesis - PKC - Palmitoylcarnitine chloride

Palmitoylcarnitine chloride

CAS No. 6865-14-1

Palmitoylcarnitine chloride( —— )

Catalog No. M33228 CAS No. 6865-14-1

Palmitoylcarnitine chloride (Palmitoyl DL-carnitine chloride) is a mitochondrial fatty acid oxidation intermediate that mediates intralipid cardioprotection.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 28 In Stock
25MG 42 In Stock
50MG 56 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Palmitoylcarnitine chloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Palmitoylcarnitine chloride (Palmitoyl DL-carnitine chloride) is a mitochondrial fatty acid oxidation intermediate that mediates intralipid cardioprotection.
  • Description
    Palmitoylcarnitine chloride is a fatty acid-derived mitochondrial substrate, and selectively decreases cell survival in colorectal and prostate cancer cells by affecting on pro-inflammatory pathways, Ca2+ influx, and DHT-like effects.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    PKC
  • Recptor
    PKC
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    6865-14-1
  • Formula Weight
    436.07
  • Molecular Formula
    C23H46ClNO4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?H2O : 50 mg/mL (114.66 mM; Ultrasonic)
  • SMILES
    [Cl-].CCCCCCCCCCCCCCCC(=O)OC(CC(O)=O)C[N+](C)(C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Al-Bakheit A, et al. Accumulation of Palmitoylcarnitine and Its Effect on Pro-Inflammatory Pathways and Calcium Influx in Prostate Cancer. Prostate. 2016 Oct;76(14):1326-37.?
molnova catalog
related products
  • Roy-Bz

    Roy-Bz is the?first?small-molecule?PKCδ-selective activator with EC50 of 58.5 nM, binds to the PKCδ-C1-domain.

  • Valrubicin

    Valrubicin (AD 32) inhibits TPA- and PDBu-induced PKC activation (IC50s: 0.85 and 1.25 μM) and has antitumor and anti-inflammatory activity.

  • Bisindolylmaleimide ...

    Bisindolylmaleimide V (BIM V) is a weak protein kinase C (PKC)inhibitor( IC50 >100 μM).